Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Five years of letrozole does not improve disease free survival for pretreated HR positive breast cancer

Dr Terry Mamounas - UF Health Center, Orlando, USA
Five years of letrozole does not improve disease free survival for pretreated HR positive breast cancer ( Dr Terry Mamounas - UF Health Center, Orlando, USA )
14 Dec 2016

Results of the BELLE-3 study of buparlisib for advanced breast cancer

Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA
Results of the BELLE-3 study of buparlisib for advanced breast cancer ( Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA )
14 Dec 2016

Epirubicin and cyclophosphamide before docetaxel in early breast cancer

Dr Bent Ejlertsen - Rigshospitalet Copenhagen, Denmark
Epirubicin and cyclophosphamide before docetaxel in early breast cancer ( Dr Bent Ejlertsen - Rigshospitalet Copenhagen, Denmark )
14 Dec 2016

Matched mutations and long term letrozole for breast cancer

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, USA
Matched mutations and long term letrozole for breast cancer ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, USA )
14 Dec 2016

neoMONARCH: CDK inhibition for HR positive, HER negative breast cancer

Dr Sara Hurvitz - Ronald Reagan UCLA Medical Center, Los Angeles, USA
neoMONARCH: CDK inhibition for HR positive, HER negative breast cancer ( Dr Sara Hurvitz - Ronald Reagan UCLA Medical Center, Los Angeles, USA )
13 Dec 2016

Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer

Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA
Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer ( Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA )
13 Dec 2016

No benefit for adjuvant ibandronate at 3 years in early breast cancer

Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands
No benefit for adjuvant ibandronate at 3 years in early breast cancer ( Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands )
13 Dec 2016

PARP inhibitory velaparib trialled in BRCA1/2 breast cancer

Dr Heather Han - H. Lee Moffitt Cancer Center, Tampa, USA
PARP inhibitory velaparib trialled in BRCA1/2 breast cancer ( Dr Heather Han - H. Lee Moffitt Cancer Center, Tampa, USA )
13 Dec 2016

Infographic: Addressing unmet needs in metastatic breast cancer

Infographic: Addressing unmet needs in metastatic breast cancer ( )
13 Dec 2016

The need to better understand pathways that drive ER＋ metastatic breast cancer

Dr Julie Gralow - University of Washington, Washington, USA
The need to better understand pathways that drive ER＋ metastatic breast cancer ( Dr Julie Gralow - University of Washington, Washington, USA )
13 Dec 2016

Barriers to oncology information access in Ireland

Dr Aoife McNamara - Irish Cancer Society, Dublin, Ireland
Barriers to oncology information access in Ireland ( Dr Aoife McNamara - Irish Cancer Society, Dublin, Ireland )
12 Dec 2016

Cancer care in North Africa

Dr Mohammed Harif - Hôpital Cheikh Khalifa, Casablanca, Morocco
Cancer care in North Africa ( Dr Mohammed Harif - Hôpital Cheikh Khalifa, Casablanca, Morocco )
12 Dec 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation